U.S. Alarm Grows Over China’s Grip on Drug Supply Chains
Washington is confronting fresh warnings that China’s expanding role in early-stage drug development and pharmaceutical supply chains could give Beijing outsized leverage over the global biopharma industry. The concern, highlighted in recent reporting and a U.S. panel warning, is not that China already dominates finished medicines, but that it is steadily building control over the upstream inputs and innovation pipeline that underpin future drug production.
